David J. Rawlings

David J. Rawlings

Auto-generated profile, based on publicly available information

David J. Rawlings

Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2012 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
DRDavid J. Rawlings
David J. Rawlings
MSMarc A. Schwartz
Marc A. Schwartz
SJShaun W. Jackson
Shaun W. Jackson
AMAlmut Meyer-Bahlburg
Almut Meyer-Bahlburg

10 April 2017 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
DRDavid J. Rawlings
David J. Rawlings
GMGenita Metzler
Genita Metzler
MWMichelle Wray-Dutra
Michelle Wray-Dutra
SJShaun W. Jackson
Shaun W. Jackson

12 September 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TATanvi Arkatkar
Tanvi Arkatkar
SDSamuel W. Du
Samuel W. Du
HJHolly M. Jacobs
Holly M. Jacobs
EDElizabeth M. Dam
Elizabeth M. Dam
BHBaidong Hou
Baidong Hou
SJShaun W. Jackson
Shaun W. Jackson
Recent studies have identified critical roles for B cells in triggering autoimmune germinal centers (GCs) in systemic lupus erythematosus (SLE) and other disorders. The mechanisms whereby B cells facilitate loss of T cell tolerance, however, remain incompletely defined. Activated B cells produce interleukin 6 (IL-6), a proinflammatory cytokine that promotes T follicular helper (TFH) cell differentiation. Although B cell IL-6 production correlates with disease severity in humoral autoimmunity, whether B cell–derived IL-6 is required to trigger autoimmune GCs has not, to our knowledge, been addressed. Here, we report the unexpected finding that a lack of B cell–derived IL-6 abrogates spontaneous GC formation in mouse SLE, resulting in loss of class-switched autoantibodies and protection from systemic autoimmunity. Mechanistically, B cell IL-6 production was enhanced by IFN-γ, consistent with the critical roles for B cell–intrinsic IFN-γ receptor signals in driving autoimmune GC formation. Together, these findings identify a key mechanism whereby B cells drive autoimmunity via local IL-6 production required for TFH differentiation and autoimmune GC formation.

7 April 2013 in Nature Immunology
Verified
Journal Article
Open access
PDF file
DBDaniela A Bermejo
Daniela A Bermejo
SJShaun W Jackson
Shaun W Jackson
MGMelisa Gorosito-Serran
Melisa Gorosito-Serran
EREva Acosta Rodriguez
Eva Acosta Rodriguez
MAMaria C Amezcua-Vesely
Maria C Amezcua-Vesely
DRDavid J Rawlings
David J Rawlings
Antibody production is the main effector function of B cells. Rawlings and colleagues show that Trypanosome cruzi induces rapid IL-17 production by B cells that is required for parasite control. Here we identified B cells as a major source of rapid, innate-like production of interleukin 17 (IL-17) in vivo in response to infection with Trypanosoma cruzi. IL-17+ B cells had a plasmablast phenotype, outnumbered cells of the TH17 subset of helper T cells and were required for an optimal response to this pathogen. With both mouse and human primary B cells, we found that exposure to parasite-derived trans-sialidase in vitro was sufficient to trigger modification of the cell-surface mucin CD45, which led to signaling dependent on the kinase Btk and production of IL-17A or IL-17F via a transcriptional program independent of the transcription factors RORγt and Ahr. Our combined data suggest that the generation of IL-17+ B cells may be a previously unappreciated feature of innate immune responses required for pathogen control or IL-17-mediated autoimmunity.

30 September 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BSBlythe D. Sather
Blythe D. Sather
GIGuillermo S. Romano Ibarra
Guillermo S. Romano Ibarra
KSKaren Sommer
Karen Sommer
GCGabrielle Curinga
Gabrielle Curinga
MHMalika Hale
Malika Hale
DRDavid J. Rawlings
David J. Rawlings
Therapeutic coding sequences can be targeted to the CCR5 locus of primary human T cells with high efficiency by using megaTAL nuclease and an AAV donor template.

11 April 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SJShaun W. Jackson
Shaun W. Jackson
HJHolly M. Jacobs
Holly M. Jacobs
TATanvi Arkatkar
Tanvi Arkatkar
EDElizabeth M. Dam
Elizabeth M. Dam
NSNicole Scharping
Nicole Scharping
DRDavid J. Rawlings
David J. Rawlings
Dysregulated germinal center (GC) responses are implicated in the pathogenesis of human autoimmune diseases, including systemic lupus erythematosus (SLE). Although both type 1 and type 2 interferons (IFNs) are involved in lupus pathogenesis, their respective impacts on the establishment of autoimmune GCs has not been addressed. In this study, using a chimeric model of B cell-driven autoimmunity, we demonstrate that B cell type 1 IFN receptor signals accelerate, but are not required for, lupus development. In contrast, B cells functioning as antigen-presenting cells initiate CD4+ T cell activation and IFN-γ production, and strikingly, B cell–intrinsic deletion of the IFN-γ receptor (IFN-γR) abrogates autoimmune GCs, class-switched autoantibodies (auto-Abs), and systemic autoimmunity. Mechanistically, although IFN-γR signals increase B cell T-bet expression, B cell–intrinsic deletion of T-bet exerts an isolated impact on class-switch recombination to pathogenic auto-Ab subclasses without impacting GC development. Rather, in both mouse and human B cells, IFN-γ synergized with B cell receptor, toll-like receptor, and/or CD40 activation signals to promote cell-intrinsic expression of the GC master transcription factor, B cell lymphoma 6 protein. Our combined findings identify a novel B cell–intrinsic mechanism whereby IFN signals promote lupus pathogenesis, implicating this pathway as a potential therapeutic target in SLE.